Form 4: Nurix Therapeutics Chief Legal Officer Exercises Options and Sells Shares

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold a portion of the acquired shares on January 31, 2025, according to a recent SEC filing.

Summary

• Christine Ring, the Chief Legal Officer of Nurix Therapeutics, executed transactions involving the company's stock on January 31, 2025.
• She exercised options to acquire 5,760 shares of common stock at a price of $1.86 per share.
• Following the option exercise, she sold 5,760 shares of common stock at a weighted average price of $19.9445 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan.
• The lowest price at which shares were sold was $19.465 and the highest price was $20.42.
• After these transactions, Ms. Ring directly owns 32,538 shares of Nurix Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions, which is neither positive nor negative in itself. It reflects routine activity.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among corporate executives to avoid accusations of insider trading.
• The reported transactions are typical for executives who receive stock options as part of their compensation package.
• The price range of the sales is within the normal fluctuations of the stock price.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the sale of shares by an executive.
• The filing provides transparency to shareholders regarding insider trading activity.

Key Dates

Keywords

insider trading, stock options, SEC Form 4, Rule 10b5-1, Nurix Therapeutics, NRIX, equity securities, Christine Ring